CELU

FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today highlighted continued progress at Fontaine Vitale, a regenerative medicine and wellness center being developed in the Sanur Special Economic Zone ("Sanur SEZ") in Bali, Indonesia, in anticipation of its grand opening in the first quarter of 2027. Developed by Genting Berhad and its Indonesian partners with strategic collaboration and input from Celularity, Fontaine Vitale is designed to serve local and international patients seeking advanced wellness, aesth

8-K - Celularity Inc (0001752828) (Filer)

10-Q - Celularity Inc (0001752828) (Filer)

FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. ("Viome"), will join its Board of Directors. Jain founded InfoSpace, Intelius, TalentWise and Moon Express and is the founder and CEO of Viome, which applies AI and molecular data to personalized health and nutrition. He joins Celularity’s Board with a consumer-focused perspective on healthcare’s shift from treating illness to helping people take a more proactive role in their health. He will bring that perspective to the challenge of bringing

8-K - Celularity Inc (0001752828) (Filer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion Company anticipates positive monthly operating cash flow by the end of Q1 2027 Philip A. Barach to join the Board, bringing financial expertise and a focus on capital discipline FLORHAM PARK, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced an initial closing generating over $10 million in gross cash proceeds from a private placement of senior secured convertible notes and warrants. The closing is part of a broader r

8-K - Celularity Inc (0001752828) (Filer)

Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome® Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, and MuseCell Innovations® Pte. Ltd. ("MCI"), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells ("DMCs") at Celularity’s Florham Park, New Jersey facility. The initial pro

FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company") today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commiss

8-K - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

25-NSE - Celularity Inc (0001752828) (Subject)

8-K - Celularity Inc (0001752828) (Filer)

8-K - Celularity Inc (0001752828) (Filer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

4 - Celularity Inc (0001752828) (Issuer)

8-K - Celularity Inc (0001752828) (Filer)

FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC ("Fountain Life"), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsi

8-K - Celularity Inc (0001752828) (Filer)

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below. Dear Fellow Shareholders, I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context of evolving clinical and regulatory progress.

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti